Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen

Tim Ferriss and Strand Therapeutics CEO Jake Becraft discuss how Strand's RNA medicines trick cancer cells into signaling the immune system to attack tumors, including a stage 4 melanoma patient whose body went from riddled with cancer to no detectable lesions. Becraft explains the difference between a good drug and a good product, the 30-year 'delivery' bottleneck in genetic medicine, and why he frames Strand through a SpaceX 'platform' analogy. A large portion covers policy: Becraft argues the US is losing biotech to China's faster, cheaper clinical-trial infrastructure and proposes replacing FDA's permission-based IND process with an Australia-style clinical trial notification system. In a follow-up recorded two months later, his Washington Post op-ed went viral, led to congressional testimony, and the core idea reached the president's legislative priorities. The pair also dig into storytelling, capital formation, and lessons from Amazon, Apple, Genentech, and Genzyme.

• Becraft showed Tim a striking before/after scan of a stage 4 melanoma patient whose body was riddled with cancer (cutaneous and visceral metastases in lungs, muscle, bone) and then had no more detectable lesions.
  00:05:41
• A year and a half into treatment, that first melanoma patient still has no detectable lesions, having previously exhausted Keytruda and multiple other lines of therapy.
  00:09:16
• Strand's core innovation: instead of injecting an immune signal that dissipates, they deliver instructions that trick the cancer cell into sending its own 'eat me' signal, dramatically improving safety and efficacy.
  00:17:37
• Of the first three patients ever on the trial in summer 2024, two of three are still on the drug 18 months later, which Becraft calls fairly shocking for a phase one trial.
  00:23:20
• Becraft's top policy ask: remove the FDA from direct permission-based oversight of first-in-human trials and shift to an Australia-style clinical trial notification (CTN) system handled by hospital IRBs.
  00:51:18
• Becraft warns the US is 'massively losing to China,' which has industrialized fast, cheap clinical-trial infrastructure creating a flywheel where Chinese companies now bring Chinese-discovered drugs to the US.
  00:59:31
• The follow-up reveals Becraft's Washington Post op-ed went viral, led to congressional testimony, and the exact FDA-reform idea appeared in the president's legislative priorities within two months.
  01:11:58
• Becraft defines a 'platform therapeutic' as common technological infrastructure to build many drugs off of, citing Strand's tumor-delivery and T-cell-delivery platforms (ST00003 coming to clinic six months ahead of schedule).
  01:32:16

• Existing ex-vivo cell therapies cost roughly $750,000 to manufacture and take three months per patient, which Becraft calls a bad product despite being a good drug.
  00:13:26
• The phenomenon where injecting one tumor causes distant tumors to shrink is called the abscopal effect or abscopal response.
  00:20:47
• Genetic medicine has been 'trapped in one organ' for 30 years: the liver, which naturally filters blood and picks up these medicines.
  00:25:58
• Strand's first IND (initial new drug application) to the FDA was about 22,000 pages long and cost millions of dollars just to assemble.
  00:52:20
• Branded medicines are about 8% of US healthcare spending while hospitals are in the high 20s (around 26%).
  00:47:23
• Genzyme once ran a van called the 'placenta mobile' that drove around Boston collecting placentas to purify a protein for a rare-disease drug.
  01:07:49
• Moderna built a COVID vaccine in 62 days from antigen identification, but only because they had spent 12 years developing the underlying RNA-vaccine platform.
  01:33:51
• Art Levinson, Genentech CEO from 1995, was also on Apple's board and became chairman replacing Steve Jobs around 2011.
  01:59:16
• The 'baby KJ' case (covered by the New York Times, involving Jennifer Doudna) was the first patient to receive a personalized systemic CRISPR-based editing therapy for a fatal liver condition.
  02:04:58
• Because INDs are so costly, boards push companies toward top hospitals like MD Anderson and Sloan Kettering, leaving many US hospitals not running first-in-human trials.
  00:54:22